#### Using quantitative magnetic resonance 1 imaging to track cerebral alterations in 2 multiple sclerosis brain: a longitudinal 3 study 4 Nora Vandeleene<sup>a</sup>, Camille Guillemin<sup>a,b</sup>, Solène Dauby<sup>a,c</sup>, Florence Requier<sup>a,b</sup>, Maëlle 5 Charonitis<sup>a,b</sup>, Daphne Chylinski<sup>a,b</sup>, Evelyne Balteau<sup>a</sup>, Pierre Maquet<sup>a,c</sup>, Emilie 6 Lommers<sup>a,c\*</sup>, Christophe Phillips<sup>a,d\*</sup> 7 8 9 <sup>a</sup> GIGA CRC in vivo Imaging, University of Liège, Liège, Belgium <sup>b</sup> Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège, 10 11 Belgium <sup>c</sup> Clinical Neuroimmunology Unit, Neurology Department, CHU Liège, Belgium 12 13 <sup>d</sup> GIGA in silico Medicine, University of Liège, Liège, Belgium 14 These authors equally contributed to the work. **Corresponding author:** 15 Christophe PHILLIPS GIGA – CRC in vivo imaging B30 16 17 Allée du 6 août 18 4000 Liège 19 Belgium 20 21 22 Acknowledgements 23 The authors are particularly thankful for the patients who took part in this study. N.V., E.L. and C.P. are supported by the Fonds de la Recherche Scientifique (F.R.S-FNRS 24 25 Belgium). 26 27 Data availability 28 The data that support the findings of this study are available on request from the 29 corresponding author. The data are not publicly available due to privacy or ethical restrictions. 30 31 32 **Conflict interests** 33 None. 34 35 36 Abbreviations: 37 ARoC: Annual Rate of Change, BPF: Brain Parenchymal Fraction, CDP: Confirmed 38 NOTE: The isability progression, UNIRF. Conventional Nagrievier Resultance Indepindence in the second secon

39	Nervous System, GMF: Grey Matter Fraction, GLMM: General Linear Mixed Model, LF:
40	Lesion Fraction, MPM: Multi-Parameter Mapping, MRI: Magnetic Resonance Imaging,
41	MS: Multiple Sclerosis, MT: Magnetization Transfer, MTR: Magnetization Transfer
42	Ratio, MTsat: Saturated Magnetization Transfer, NABT: Normal Appearing Brain
43	Tissue, NACGM: Normal Appearing Cortical Grey Matter, NADGM: Normal Appearing
44	Deep Grey matter, NAWM: Normal Appearing White Matter, NEDA-3: No Evidence of
45	Disease Activity, RRMS: Relapsing-Remitting Multiple Sclerosis, PD: Proton Density,
46	PMS: Progressive Multiple Sclerosis, qMRI: Quantitative Magnetic Resonance Imaging,
47	<b>R1</b> : Longitudinal Relaxation Rate (1/T1), <b>R2*</b> : Transverse Relaxation Rate (1/T2*), <b>TIV</b> :
48	Total Intracranial Volume, TPM: Tissue Probability Map, US: Unified Segmentation,
49	USwL: Unified Segmentation with Lesion

# 50 Abstract

51 Quantitative MRI quantifies tissue microstructural properties and supports the 52 characterization of cerebral tissue damages. With an MPM protocol, 4 parameter maps 53 are constructed: MTsat, PD, R1 and R2\*, reflecting tissue physical properties 54 associated with iron and myelin contents. Thus, qMRI is a good candidate for *in* vivo 55 monitoring of cerebral damage and repair mechanisms related to MS. Here, we used 56 gMRI to investigate the longitudinal microstructural changes in MS brain.

57 Seventeen MS patients (age 25-65, 11 RRMS) were scanned on a 3T MRI, in two 58 sessions separated with a median of 30 months, and the parameters evolution was 59 evaluated within several tissue classes: NAWM, NACGM and NADGM, as well as focal 60 WM lesions. An individual annual rate of change for each qMRI parameter was 61 computed, and its correlation to clinical status was evaluated. For WM plaques, three 62 areas were defined, and a GLMM tested the effect of area, time points, and their 63 interaction on each median qMRI parameter value.

Patients with a better clinical evolution, i.e., clinically stable or improving state,
 showed positive annual rate of change in MTsat and R2\* within NAWM and NACGM,
 suggesting repair mechanisms in terms of increased myelin content and/or axonal
 density as well as edema/inflammation resorption. When examining WM lesions, qMRI
 parameters within surrounding NAWM showed microstructural modifications, even
 before any focal lesion is visible on conventional FLAIR MRI.

The results illustrate the benefit of multiple qMRI data in monitoring subtle changes within normal appearing brain tissues and plaque dynamics in relation with tissue repair or disease progression.

74	Keywords:
75	Quantitative MRI, relaxometry, longitudinal analysis, multiple sclerosis.
76	
77	Key points:
78	Patients with a better clinical evolution showed microstructural improvement
79	in term of MTsat and R2* increase in their normal appearing tissue, suggesting
80	repair mechanisms.
81	• Using qMRI allows to detect modifications in tissue microstructure in normal
82	appearing tissues surrounding lesions several months before they are visible on
83	conventional MRI.
84	
85	

# 86 **1. Introduction**

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). Plaques are the pathological hallmark of MS. They are spread in acute, focal, disseminated and recurrent way throughout the CNS and harbor variable degrees of inflammation, demyelination, gliosis and axonal injury [1, 2]. Plaques are not restricted to the white matter (WM), but are also present in the cortex and deep grey matter (GM) [3-5].

92 Over and above focal WM lesions, an early, diffuse and chronic inflammation within the 93 normal appearing white matter (NAWM) and grey matter (NAGM) is ultimately responsible 94 for diffuse neuro-axonal loss and neurodegeneration, which is deemed responsible for a 95 progressive accumulation of disability [3, 4, 6].

96 By contrast, effective repair mechanisms can occur within focal lesions but probably also in 97 normal appearing brain tissue (NABT) [7]. However, our understanding of these complex 98 processes is still fragmentary. The difficulty of acquiring histopathological data on MS patients 99 at various stages of the disease makes it challenging to describe the time course of injury and 100 potential repair mechanisms in MS. Consequently, there is a need for new imaging techniques 101 to improve the *in-vivo* monitoring of brain damages formation, progression and repair in MS 102 [8].

103 Conventional MRI (cMRI) readily depicts focal WM lesions on T2/FLAIR sequences and is able 104 to distinguish between acute and allegedly chronic lesions. T2-hyperintensities in cMRI 105 constitute the keystone of McDonald diagnostic criteria [9] and also make an important 106 contribution to the monitoring of WM lesion burden. Unfortunately, cMRI sequences do not 107 sensitively detect cortical lesions and diffuse changes in NABT, due to a rather low sensitivity 108 of cMR imaging for cortical lesions, mixed contrast weight, and an overall limited 109 histopathological specificity within cerebral tissues. Quantitative MRI (qMRI) potentially

110 overcomes these limitations by quantifying physical microstructural properties of cerebral 111 tissue in standardized units. qMRI is more sensitive but also more specific to microstructural 112 properties of CNS tissues. Magnetization transfer ratio (MTR) was regularly linked to cerebral 113 macromolecular content detected by a greater percentage loss of magnetization in voxels with 114 a higher myelin content and axons density [10-12]. Post-mortem studies comparing the 115 relative contribution of these two factors indicate that myelin has a stronger and more direct 116 influence on MTR than the axonal density, which is considered as a T1-dependent effect. 117 Tissue water content (inflammation, edema...), another T1-dependent effect, also accounts 118 for MTR variability [11, 13, 14]. However, the MT saturation (MTsat) map offers a measure 119 which, unlike MTR, is minimally affected by longitudinal relaxation and B1 mapping 120 inhomogeneities [15], increasing its sensitivity to myelin content. Moreover, the brain 121 contrast to noise ratio is larger for the MTsat map than for MTR, thus improving brain tissue 122 segmentation in healthy subjects [11, 16]. R2\* was usually linked to iron and myelin contents, 123 as paramagnetic iron and diamagnetic myelin generate microscopic field gradients in the CNS, 124 thus shortening T2\* and increasing R2\* (1/T2\*). Orientation and density of myelin fibers are 125 also a determining factor of R2\* values [17-19]. Iron is probably a key factor in MS monitoring 126 as it was shown that aberrant iron metabolism occurs in the course of the disease [20]. 127 Particularly increased iron concentration within chronic active lesions (i.e iron rim lesion) or 128 deep grey matter structures was observed [20]. Regarding the longitudinal relaxation rate R1 129 (1/T1), its three major determinants in the CNS are tissue myelination and associated axons, 130 iron, and extracellular water contents [19, 21, 22]. Finally, proton density (PD) mostly reflects 131 the free water content of the brain [23].

A number of cross-sectional studies using a combination of MT, R1, R2\* or PD parameters,
 comparing MS patients to healthy controls, reported significant changes in the microstructure

of NABT, such as a decrease in MT, R1 and R2\* and an increase in PD in patients [24-32]. Few
studies addresses the longitudinal variations in qMRI. R2\* [33-35], PD and T1 were reported
to increase in the basal ganglia over a period of a year [36], whereas a decrease in MTR in
NAWM was reported over one [37] or two years [38].

Regarding focal WM plaques, qMRI emerges as an appealing biomarker to describe the dynamic processes of demyelination and remyelination. For instance, MTR was shown to sharply decrease within gadolinium enhancing lesions before recovering during the subsequent months [39-41], and within NAWM days to weeks before the formation of a new active lesion [42, 43].

Because each qMRI parameter is differently sensitive to histologically measured iron and myelin contents, this approach might become a fundamental tool for longitudinal *in vivo* Monitoring of MS lesions and NABT evolution at the tissue microstructural level.

In this longitudinal study, we investigate the evolution of four simultaneously acquired qMRI parameters (MTsat, PD, R1, R2\*) within NABT and WM lesions of 17 MS patients - relapsing remitting (RRMS) and progressive MS (PMS) - who were scanned two times with at least a one-year interval, following the same multi-parameter mapping (MPM) protocol at 3 Tesla [10, 44].

We assessed the time course of parameter values in several tissue classes: normal appearing white matter (NAWM), normal appearing cortical and deep GM (NACGM and NADGM) as well as focal WM lesions. In addition, we related longitudinal qMRI changes within NABT to clinical course.

#### 155 **2. Materials and methods**

### **2.1 Population**

157 Seventeen patients, recruited at the specialized MS outpatient clinic of the CHU Liège, 158 Belgium, with a diagnosis of MS according to the McDonald criteria 2010 [45], were gathered 159 from two studies: ten of them were part of the work reported by Lommers et al. 2019 [24], 160 the other seven were recruited from another MS study taking place at the GIGA Cyclotron 161 Research Centre – In Vivo Imaging (Liège, Belgium) [46]. For the first study (10 subjects), the 162 inclusion criteria were (1) age between 18 and 65 years ; (2) Expanded Disability Status Scale 163 (EDSS) inferior or equal to 6.5; (3) absence of relapse within the previous four weeks; (4) 164 absence of IVMP administration for at least 6 months prior to the study. Both RRMS and PMS 165 patients were recruited. The second study (7 subjects) differs a bit as it comprises only RRMS 166 patients, and the inclusion criteria were (1) age between 18 and 45, (2) EDSS between 0 and 167 4, (3) absence of relapse for at least 6 months prior to the study, (4) disease duration was 168 below or equal to 5 years, (5) absence of IVMP administration for at least 6 months prior to 169 the study. For both studies, compatibility with MRI and absence of other 170 neurological/psychiatric diseases were required. These studies were approved by the local 171 ethics committee (approval numbers B707201213806 and B707201835630, respectively). All 172 patients were followed up and scanned twice on the same 3T MRI scanner, every 1 to 3 years. 173 For each of the 17 MS patients, data from two MRI sessions were available, at T0 and T1. This 174 cohort included 11 RRMS and 6 (primary and secondary) PMS patients. Thirteen were 175 receiving disease-modifying treatments (DMTs). The patients' median age was 36 years 176 (range: 25-65) and the median time interval between two scans was 30 months (range: 14-177 61). Demographic data appears in Table 1. Extended individual information appears in 178 Supplementary data.

179

# 180 **2.2 MR image acquisition**

181 MRI data were acquired on a 3T whole-body MRI-scanner (Magnetom Prisma, Siemens 182 Medical Solutions, Erlangen, Germany). The whole-brain MRI acquisitions included a multi-183 parameter mapping protocol (MPM), from which one can simultaneously estimate 184 (semi)quantitative maps of magnetization transfer saturation (MTsat), proton density (PD), 185 transverse relaxation (R1) and effective longitudinal relaxation (R2\*). This protocol arising 186 from an international collaborative effort [10, 44], has already been used to study brain 187 microstructure in various conditions including normal aging [9, 44, 47], brain tumor [48], 188 Parkinson's disease [49-51] as well as MS. It consists of three co-localized 3D multi-echo fast 189 low angle shot (FLASH) acquisitions at 1mm<sup>3</sup> resolution and two additional calibration 190 sequences to correct for inhomogeneities in the RF transmit field [52, 53]. The FLASH datasets 191 were acquired with predominantly PD, T1 and MT weighting, referred to in the following as 192 PDw, T1w and MTw, at multiple echo times. All three had high bandwidth to minimize off-193 resonance and chemical shift artifacts. Volumes were acquired in 176 sagittal slices using a 194 256x224 voxel matrix. GRAPPA parallel imaging was combined with partial Fourier acquisition 195 to speed up acquisition time to approximately 20 min. An additional FLAIR sequence was 196 recorded with spatial resolution 1mm<sup>3</sup> and TR/TE/TI=5000ms/516ms/1800ms. Extra B1 field 197 mapping images (transmit B1+ and receive B1- fields) were also acquired to reduce spatial 198 inhomogeneities related to B1 effect. This was essential for proper quantification of T1 (or 199 R1=1/T1) in particular. Finally, B0 field mapping images, corresponding to both magnitude 200 images and pre-subtracted phase image, were acquired for image distortions corrections. A 201 summary of the acquisition parameters appears in Supplementary data.

202 Note that these MR sequences at 3 Tesla are not sensitive to cortical lesion as described in 203 [54, 55] although a few lesions at the cortico-subcortical border were detected. Quantification 204 of cortical parameters is thus confounded by voxels potentially located within cortical lesions.

205 **2.3 MR image processing** 

All data processing was performed in Matlab (The MathWorks Inc., Natick, MA, USA) using SPM12 (www.fil.ion.ucl.ac.uk/spm) and three additional dedicated SPM extensions: the Lesion Segmentation Tool (LST) version 1.2.3 (www.statisticalmodelling.de/lst.html) [56], the

209 "quantitative MRI and in vivo histology using MRI" toolbox (hMRI, http://hmri.info) [10], and
210 "US-with-Lesion" tool (USwL, https://github.com/CyclotronResearchCentre/USwLesion).

211 Quantitative maps - MTsat, PD, R1 and R2\* - were estimated using the hMRI toolbox. T1w, 212 PDw and MTw images acquired at multiple echo times (TE) were extrapolated to TE=0 to 213 increase signal-to-noise ratio and remove the otherwise remaining R2\* bias [10, 24, 57]. The 214 TE=0 extrapolated MTw, PDw and T1w images were used to calculate MT saturation, R1 and 215 apparent signal amplitude A\* maps. PD map was derived from A\* map, which is proportional 216 to proton density. All quantitative maps were corrected for inhomogeneities from local RF 217 transmit field (B1+), and R1 quantitative maps were further corrected for imperfect RF spoiling 218 using the strategy of Preibisch and Deichmann [58]. The receive bias field map (B1-) was used 219 to correct PD maps for instrumental biases. The R2\* map was estimated from all three multi-220 echo series (MTw, PDw and R1w) using the ESTATICS model [57].

After generating quantitative maps using the hMRI toolbox for all sessions, spatial preprocessing involved the following steps (Figure 1): within-patient registration brought the two serial MR data sets into the individual TO space, using the longitudinal registration tool from SPM [59]. For each individual patient, a preliminary WM lesion mask was generated based on FLAIR and T1w images by the lesion growth algorithm implemented in the LST

226 toolbox [56], followed by manual corrections by an MS expert (EL) to remove 227 aberrant/artefactual lesion detections [24]. The images were then segmented using the USwL 228 toolbox, which consists of an extended version of the traditional Unified Segmentation (US) 229 algorithm [60] and includes an additional tissue class representing the WM lesion(s). The US-230 with-lesion method internally generates a subject-specific extended set of tissue probability 231 maps (TPM) [61]: an extra tissue class, based on the smoothed preliminary lesion mask warped 232 into template space (using cost function masking during normalization [62]), is added to 233 account for the lesion, and the original white matter prior map is updated accordingly [63]. 234 The grey matter TPM was not updated due to a very low number of lesions present in the 235 cortical ribbon. Multi-channel segmentation was conducted, using MTsat, PD, R1 and FLAIR 236 images. This pipeline did not use the PD-, T1- and MT-weighted images acquired for the MPM 237 maps construction, but the parametric maps themselves instead. In this way, voxels do not 238 depict MR intensities but rather physical quantitative parameters. The method generated the 239 segmented tissue classes (a posteriori tissue, including lesion, probability maps), as well as 240 spatial warping into standard template space. The preliminary lesion mask was used as input 241 for the first session data (at T0) then the *a posteriori* lesion map generated at this initial step 242 served as prior to the subsequent session (at T1).

Segmentation teased out the different tissue classes of interest: NAWM, NACGM and NADGM, as well as WM lesions. To analyze the microstructure within those tissue classes, *a posteriori* tissue maps were binarized and tissue-specific independent masks were constructed: each voxel is assigned to one single tissue class with the highest probability for that voxel (provided that this probability was above 0.2). The lesion binary mask was further cleaned for lesions <10mm<sup>3</sup> which likely resulted from segmentation errors. Finally, binarized tissue class masks were in turn applied on the MPM maps to extract voxel values inside them.

# 250 **2.4 Brain volume change**

251 Volumetric changes were investigated using the USwL a posteriori tissue probability maps. The 252 following measures of brain volume were computed for each session of each participant: (1) 253 Total intra-cranial volume (TIV) = volume (NAWM + GM + CSF + lesions), (2) brain parenchymal 254 fraction (BPF) = volume (NAWM + GM + lesions)/TIV, (3) Gray matter fraction (GMF) = volume 255 (GM)/TIV, and (4) lesion fraction (LF) = volume (lesion)/TIV. The percentage of change 256 between both scanning sessions was evaluated for each volumetric measurement, then 257 annualized changes were computed by dividing these measures by scan intervals (in years). 258 Results were directly analysed with a t-test (testing if significantly different from 0 at p < .05), 259 but also in the same way as the normal appearing tissues MR parameters in relation to the 260 patients' clinical status (see next section).

261

# 2.5 Analysis of normal appearing tissues

The median value of quantitative MRI parameters was extracted from the three normal appearing tissues (NAWM, NACGM and NADGM), and an individual annual rate of change (ARoC) was computed for each parameter in each tissue class, based on the initial and final values and accounting for the time interval (in years) between scans. This rate of change in qMRI parameters served as dependent variable in a general linear model testing the effect of clinical status:

268 
$$Y = \beta_0 + \beta_1 X_{status} + \epsilon$$

269

270 *Y* is the ARoC for a qMRI parameter and tissue class,  $\beta$ 's are the regression parameters 271 corresponding to the associated regressor (with  $\beta_0$  the intercept), and  $\epsilon$  the residuals.  $X_{status}$ 272 is a binary categorical variable representing the patient's disease activity status: a status score 273 of 1 was assigned to patients stable or improving from T0 to T1.

274 This patient status  $X_{status}$  was derived from one score of disease activity: NEDA-3 (No 275 Evidence of Disease Activity [64]), a composite of three related measures of disease activity. 276 A score of 0 was assigned in the presence of new clinical relapses (only concerning RRMS 277 patients) and/or MRI activity (new or enlarged lesions visible on FLAIR T2 or Gadolinium-278 enhanced images) and/or sustained disability progression over six months based on Expanded 279 Disability Status Scale (EDSS). For both RRMS and PMS patients, disability progression was 280 defined as a 1.0-point increase if the EDSS score was  $\leq$  4.0 at baseline and as a 0.5 point 281 increased if the baseline EDSS score was > 4.0. The threshold of 4.0 was proposed in this study 282 because it is considered as a milestone regarding ambulatory performance.

NEDA-3 and was evaluated at mid- and end-scanning interval, and a final status score of 0 was given only to patients for which disease activity or progression was noted in both cases, indicating a clear progression of the disease over the whole interscan interval.

The influence of several clinical measurements such as 25 FWT, 9HPT and SDMT was also considered to refine the evaluation of disease activity. However complete data were lacking for several patients. Moreover, when available, these additional clinical parameters did not modify the final  $X_{status}$ . Longitudinal clinical information allowing to derive the disease activity status for each subject appears in Table 2. Additional clinical information concerning annual relapse rate and treatment administration appears in Supplementary material.

292 Permutation tests were employed for inferences [65]. R-squared value was tested against 293 computed statistics after permutation of the data. For a number *n* of permutations, the 294  $X_{status}$  values were randomly shuffled (constructing a new regressor written  $X_{status}^{\pi}$ ), tested 295 against the unchanged response *Y*, and generating each time a permuted R-squared value 296 (noted  $R_{\pi}$ ,  $R_{obs}$  being the true R-squared value computed without permutation of the data).

297 The condition  $X_{status} \neq X_{status}^{\pi}$  is verified at each permutation. After *n* permutations (with *n* 298 = 5000 in this study), a *p*-value was computed based on the following formula:

299 
$$p = \frac{\#(R_{\pi} > R_{obs})}{n+1}$$

which estimates the probability of obtaining  $R_{obs}$  under the null hypothesis that Y is not correlated to  $X_{status}$ . The null hypothesis is rejected if p < .05 FDR-corrected for multiple comparisons [66], for the 12 tests performed (3 tissue classes with 4 qMRI parameters).

303 Two-tailed t-tests were applied *post-hoc* on the significant results of permutation tests to

304 compare the ARoC distribution between disease status, i.e.,  $X_{status} = 0$  against  $X_{status} = 1$ .

305 Inferences were conducted at a significance level of .05.

The same pipeline was applied to the brain volumetric changes (BPF, GMF and LF) to test theircorrelation to the disease activity status.

308

# 2.6 Analysis of lesions and peripheral tissues

309 For white matter lesions analysis, we did not use ARoC but exploited directly the gMRI 310 parameters voxel values. Importantly, with USwL segmentation, the prior lesion mask is only 311 used in a probabilistic way and the estimated posterior lesion map, obtained using MTsat, PD, 312 R1 and FLAIR images, typically showed more extended lesion than clinically visible on the 313 FLAIR image alone. Therefore, we separated focal lesions detected on FLAIR images, with LST 314 segmentation and visual inspection, from their peripheral regions detected on qMRI maps. 315 Two different peripheral regions were considered: one for each time point (T0 and T1). 316 Therefore, at T0, three distinct lesion-related regions were isolated:

- The lesions, as clinically defined, pertaining to hyperintensity on the conventional FLAIR
   MR image acquired at T0. These are referred to as 'focal FLAIR lesion'.
- The peripheral region detected on qMRI maps at TO, at the borders of (but not including)
- 320 the focal FLAIR lesion. Those are referred to as 'initial peripheral lesion'.

The peripheral region, detected on qMRI maps at follow up, bordering (but not including)
 the initial peripheral lesion, further referred to as 'later peripheral lesion'. This was
 computed by masking out the T1 lesion mask with the T0 lesion mask. This region allows
 us to determine whether its microstructure at T0 forebodes a full-blown plaque,
 detectable during follow up. Those sometimes appear hyperintense on FLAIR images.

The three areas were compared between each other and with NAWM, in order to characterize them on a microstructural basis (Figure 2). For an accurate lesion-by-lesion analysis, only enlarging lesions, i.e., present in the three masks, were considered for these comparisons. NAWM region consisted of all white matter voxels which did not belong to any of the three

lesion-related regions. The four areas are not overlapping as no voxel could belong to morethan one class at the same time.

332 For all participants, MTsat, PD, R1 and R2\* median values were extracted from each lesion 333 area, considering lesions individually (between 2 and 66 measurements per subject). Similarly, 334 the median qMRI values within NAWM were also extracted (one measurement per subject). 335 These values were extracted from TO and T1 scans separately. Statistical analyses were 336 performed in SAS 9.4 (SAS Institute, Cary, NC). None of the qMRI parameter was normally 337 distributed, therefore we applied a log transformation on each of them prior to statistical 338 analysis. For each qMRI parameter, a separate Generalized Linear Mixed Model (GLMM) 339 tested the effect of areas (NAWM and the three lesion-related areas), and time points (T0 and 340 T1), as well as their interaction (i.e., area\*time), on the median gMRI parameter value, with a 341 first-order autoregressive variance/covariance model and participants as a random factor 342 (intercept). The degrees of freedom were estimated using Kenward-Roger's method. 343 Statistical significance was estimated at p < .05 after adjustment for multiple comparison 344 using Tukey's procedure.

# **3**45 **3. Results**

### **346 3.1 Volume changes**

Brain parenchymal fraction (BPF) annually decreased between T0 and T1 by -0.67  $\pm$  1.12% (significantly different from zero; paired-sample t-tests; t(16) = 2.57; p = .0204) whereas lesion fraction (LF) increased by 22.88  $\pm$  26.13% (t(16) = -3.70; p = .0019). GM fraction

350 (GMF) non-significantly decreased by -0.30  $\pm$  1.44%.

# **3.2 Analysis of normal appearing tissues**

As expected, changes in MTsat and R2\* within normal appearing brain tissues (NABT) between
T0 and T1 varied across subjects (Figure 3). PD and R1 exhibited similar behaviors, see
Supplementary data.

At the group level, with the regression analysis and permutation inference, we observed that the annual rate of change (ARoC) of MTsat and R2\* positively regressed with disease status as

357 follows (Table 3): MTsat in NAWM and NACGM and R2\* in NAWM significantly increased in

358 patients who fare well ( $X_{status} = 1$ ).

359 *Post-hoc* t-tests applied on these significant results for a clearer illustration of the difference

in disease status (Figure 4) were all significant at a level of .05.

361 Regarding BPF and LF, their correlation to the disease activity status was not significant (Table
362 3), suggesting that qMRI parameters are more sensitive to subtle microstructural changes in

- 363 normal appearing tissues over time than global morphological measurements
- 364

# 3.3 Analysis of lesion microstructure

365 The number of enlarging WM lesions between T0 and T1 varied from 2 to 66 across patients,

366 for a total of 741 identified enlarging lesions among all subject, corresponding on average

among patients to 63% (±31%) of the amount of initial focal lesions. The number of enlarging

368 lesions did not significantly differ between patients' disease status groups (t(15) = .244, p =

369 .811).

370 GLMMs found a significant effect of areas (3 lesion regions and NAWM) for MTsat, R1, R2\* and PD median (MTsat:  $F_3 = 35.34$ , p < .0001, PD:  $F_3 = 68.03$ , p < .0001, R1:  $F_3 =$ 371 40.26, p < .0001, R2\*:  $F_3 = 32.32$ , p < .0001). By contrast, neither time effect (T0 vs T1; 372 373 MTsat:  $F_3 = 0.36$ , p = .5481, PD:  $F_3 = 1.20$ , p = .2735, R1:  $F_3 = 2.05$ , p = .1520, R2\*: 374  $F_3 = 2.86$ , p = .0911), nor the area\*time interaction (MTsat:  $F_3 = 0.09$ , p = .9671, PD:  $F_3 = 0.14$ , p = .9346, R1:  $F_3 = 0.14$ , p = .9331, R2\*:  $F_3 = 0.40$ , p = .7565) were 375 376 significant, suggesting the microstructural stability of the initial lesion core. Post-hoc tests 377 confirmed significant differences between the four tissue areas.

At times T0 and T1, MTsat, R1 and R2\* values were significantly larger in the initial peripheral lesion than FLAIR lesion, in the later peripheral lesion than the initial one, and in the NAWM than later peripheral lesion. The reverse was observed for PD. The significant difference in parameters between initial and later peripheral lesion at T0 suggests that subtle microstructural changes appear in the periphery of the initial lesion, months before their detection as focal FLAIR lesions at T1. Adjusted *p*-values appear in Figure 5. Detailed statistical results of the GLMM's appear in Supplementary data.

**4. Discussion** 

This longitudinal study followed up volumetric data and qMRI brain metrics (MTsat, PD, R1, R2\*) in 17 patients with multiple sclerosis for a median time interval of 30 months. The main results are threefold. First, the microstructure of normal appearing brain tissues changes over time and these modifications concur with, and potentially drive, clinical evolution. This critical finding suggests that repair mechanism and edema resorption can be monitored *in vivo*. Second, the microstructure within WM plaques is remarkably heterogeneous. Importantly, at

392 their periphery, microstructural alterations foreshadow their expansion, as detected by 393 conventional MRI. Third, as expected, we observed a small but significant brain atrophy and 394 lesion load increase with time.

## 395 Quantitative MRI parameter time course within NABT

396 In this study, we used a multiparameter mapping protocol that was gradually optimized and 397 validated for multi-centric studies [67]. It provides high-resolution maps of multiple gMRI 398 parameters from data acquired during a single scanning session of acceptable duration. A 399 number of cross-sectional studies using a combination of MT, R1, R2\* or PD parameters 400 reported significant changes in the microstructure of NABT in MS [24-32]. By contrast, 401 longitudinal analyses of multiparameter qMRI data are scarce. A progressive shortening of 402 T2/T2\* [68] or increase in R2\* [33-35] was reported within the basal ganglia, suggesting 403 increased of myelin and/or iron contents as well as edema resorption. Likewise, PD and T1 404 increased within a year, suggesting a demyelination and/or axonal loss [36]. MTR progressively 405 decreases in NAWM of MS patients over one [37] or two years [38]. These abnormalities tend 406 to be more pronounced in progressive phenotypes [69] and were associated to a slow, diffuse 407 and global myelin pathology.

408 Here, we showed that MTsat within NAWM and NACGM and R2\* values within NAWM 409 increase in clinically stable or improving patients. Because MTsat and R2\* both correlate with 410 myelin content [11, 47, 70-73], our results suggest repair mechanisms within NABT of patients 411 who are responding to disease modifying treatments, despite the initial myelin/axonal loss 412 and independently from WM focal lesion evolution. Such increases could also be explained by 413 an edema/inflammation resorption, but less likely than myelin/axonal density changes since 414 MTsat is the least dependent to water content among the four qMRI parameters. These 415 results echo cross-sectional analyses showing that healthy controls (HC) have higher MTsat

and R2\* values within the same tissue classes compared to MS patients [24]. Annual rates of
change of R1 and PD within NABT were not significantly associated with the individual clinical
status in this study, although R1 reduction within NABT has already been reported in cross
sectional [24, 29, 30] and longitudinal [36] studies comparing MS subjects to HC.

420 Lesion microstructure

421 Focal inflammatory demyelinating lesions have been extensively characterized and are 422 traditionally classified as active, chronic active (smoldering) or inactive plaques according to 423 the presence and distribution of plaque-infiltrating macrophages/microglia [74-76]]. Focal 424 WM pathology is a constantly evolving process including episodes of demyelination and 425 remyelination but also accumulation of irreversible axonal damage. Age, disease duration, 426 clinical phenotype as well as disease modifying treatment all contribute to the dynamic nature 427 of focal WM pathology [75, 77]. This accounts for the large inter- and intra-individual heterogeneity of MS, which conventional MRI is largely unable to capture. By contrast, 428 429 quantitative MRI parameters are sensitive to myelin, axonal as well as iron contents and 430 appear as promising markers of plaque dynamics. For instance, MTR was shown to sharply 431 decrease within gadolinium enhancing lesions before recovering during the subsequent 432 months [39-41]. Likewise, reduction of MTR within NAWM, days to weeks before the 433 formation of a new active lesion was also demonstrated [42, 43], and long-term MTR changes 434 in WM plaques were observed in relation with disease progression [69, 78]. The present study 435 broadens the quantitative characterization of plaque dynamics, in keeping with previous 436 longitudinal studies [68, 79]. Two important findings emerge from the results. First, qMRI 437 refines lesion segmentation, as compared to the processing based on the sole FLAIR image. In 438 consequence, the initial lesion revealed by qMRI is typically wider that the plaque detected in FLAIR. Its periphery is characterized by a decrease in MTsat and R2\* as compared to NAWM, 439

440 suggesting an incipient demyelination, reminiscent of the so-called 'periplaques' [80]. 441 Moreover, MTsat, R2\* and R1 values progressively decrease from NAWM to plaque core, 442 suggesting a centripetal loss of myelin content. Second, plaque microstructure is altered in 443 plaque periphery before any observable change in conventional MRI signals. This finding 444 suggests, in keeping with neuropathological observations [75, 77, 81, 82] that subclinical 445 ongoing inflammation and/or demyelination takes place in the periphery of an active plaque, 446 well before it is detectable on FLAIR or T1 post-gadolinium sequences. If confirmed on larger 447 population samples, this finding might significantly modify treatment management in MS 448 patients.

449 Another plausible hypothesis explaining the progressive decrease of R2<sup>\*</sup> in initial and later 450 peripheral regions is that iron-containing macrophages could be removing iron from the 451 lesions through perivascular drainage into the extracellular compartment. Previous 452 neuropathological studies have reported an iron loss at the edges of a subset of MS lesions, 453 depending on their type (active, inactive, smoldering, etc.) as well as the patient's age and 454 disease duration [83, 84]. Due to the limited sensitivity of R2\* to local iron concentration as 455 compared, for example, to the combined use of R2\* and quantitative susceptibility mapping 456 (QSM) [18], validating this theory would require additional measures which can better 457 describe iron dynamics in MS lesions and NAWM.

# 458 Volumetric Data

459 CNS atrophy occurs in all stages of MS, since the preclinical phase of the disease and 460 progresses throughout its course, at a much higher rate than one reported in normal aging 461 [85-88]. In this study, the annual brain percentage volume loss at the group level was 0.67%, 462 which is in line with previous publications [89]. We also showed a significant increase in lesion 463 fraction. Volumetric data (ARoC's) were highly variable across subjects: changes in BPF range

464 from -2.52 to 1.17% and LF from -0.78 to 103.06%. This variability arises from a large number 465 of factors which do not necessarily relate to MS: age, disease duration, disease phenotype, 466 disease modifying treatment, circadian rhythm, hydration... [87, 88]. 467 Moreover, annual changes in brain parenchymal fraction as well as lesion fraction only 468 partially correlated to patients' disease status, in accordance with a large amount of 469 publications [36, 90]. This highlights the lack of specificity and sensitivity of volumetric 470 measurements, at least at the individual level.

471 It can appear odd that brain atrophy progresses in parallel to repair mechanisms, as suggested 472 by gMRI parameters. However, BPF reduction is minimal, and is not significant (see Table 3) 473 between T0 and T1. One should keep in mind that cortical atrophy is an irreversible 474 phenomenon. Given the inter- and intra-individual heterogeneity of MS progression, it is possible that patients who have undergone neuron- axonal loss at some point in the disease 475 476 might be able to remyelinize their remaining axons, hopefully through therapeutic 477 intervention or lifestyle changes. Besides, axonal remyelination is not always effective. Here 478 we showed that variations in MTsat and R2\* correlated to the disease activity status, but our 479 clinical evaluation based on EDSS is undoubtedly imprecise. Once again, the size and 480 heterogeneity of our cohort limits the interpretation of such results.

#### 481 **Study limitation**

As mentioned here above, the small size and heterogeneous aspect of the present dataset constitute major limitations of this study. Indeed, it is composed of only 17 patients, with a rather broad range of characteristics such as age, disease duration, disease phenotype, disease modifying treatment, etc., which are known to influence the disability state of the patient and thus their ability to put together repair mechanisms within cerebral tissues [1, 75-77, 91, 92]. In addition, the time interval between two scanning sessions varied rather widely

across patients (between 14 and 61 months), although it was brought back to an annual rate
where possible. All of these parameters were imposed by standard clinical follow up.
Therefore, these results should not be over-interpreted but are nevertheless promising and
call for a replication with a larger and more homogeneous or controlled set of MS patients.
Larger longitudinal studies are currently being held and will probably confirm these
preliminary results.

494 A second limitation is the absence of longitudinal MRI data acquired in a control group of 495 healthy subjects. However, we considered that literature of longitudinal studies of healthy 496 subjects that analysed tissue microstructure could constitute a solution for comparison with 497 MS patients. For example, in Bonnier et al. (2017) [68], the control group did not show any 498 significant differences regarding T1, T2\* or MTR measurements over two years, and the 499 median age of their group is quite similar to ours (34,3 vs 36 years). Also, in Elkady et al. (2018) 500 [33], they found no longitudinal R2\* effect in their control groups, even with an age range 501 superior to ours. Moreover, the median age of our population (< 60 years), as well as the 502 short period between two scanning sessions (median of 14 months), suggests that 503 microstructural alterations would not be noticeable in a healthy participants group, as many 504 quantitative ageing studies detected differences over much larger time periods [44, 70, 93].

## **5**05 **5. Conclusion**

506 These preliminary results highlight the relevance of multiple qMRI data in the monitoring of 507 MS disease, highlighting subtle changes within NABT and plaque dynamics in relation with 508 repair or disease progression. Of course, large scale longitudinal study would be needed to 509 reproduce these findings and better exploit the full potential of qMRI parameters.

# 511 References

[1] Lassmann, Hans. "Pathology and Disease Mechanisms in Different Stages of Multiple
Sclerosis." Journal of the Neurological Sciences 333, no. 1–2 (October 2013): 1–4.
<a href="https://doi.org/10.1016/j.jns.2013.05.010">https://doi.org/10.1016/j.jns.2013.05.010</a>.

516 [2] Trapp, Bruce D., John Peterson, Richard M. Ransohoff, Richard Rudick, Sverre Mörk, and 517 Lars Bö. "Axonal Transection in the Lesions of Multiple Sclerosis." *New England Journal of* 518 *Medicine* 338, no. 5 (January 29, 1998): 278–85.

519 <u>https://doi.org/10.1056/NEJM199801293380502</u>.

520

[3] Haider, Lukas, Tobias Zrzavy, Simon Hametner, Romana Höftberger, Francesca Bagnato,
Günther Grabner, Siegfried Trattnig, Sabine Pfeifenbring, Wolfgang Brück, and Hans
Lassmann. "The Topograpy of Demyelination and Neurodegeneration in the Multiple Sclerosis
Brain." *Brain* 139, no. 3 (March 2016): 807–15. <u>https://doi.org/10.1093/brain/awv398</u>.

525

[4] Kutzelnigg, Alexandra, Claudia F. Lucchinetti, Christine Stadelmann, Wolfgang Brück,
Helmut Rauschka, Markus Bergmann, Manfred Schmidbauer, Joseph E. Parisi, and Hans
Lassmann. "Cortical Demyelination and Diffuse White Matter Injury in Multiple Sclerosis." *Brain* 128, no. 11 (November 1, 2005): 2705–12. <u>https://doi.org/10.1093/brain/awh641</u>.

530

[5] Gh Popescu, Bogdan F, and Claudia F Lucchinetti. "Meningeal and Cortical Grey Matter
Pathology in Multiple Sclerosis." *BMC Neurology* 12, no. 1 (December 2012): 11.
https://doi.org/10.1186/1471-2377-12-11.

535	[6] Frischer, Josa M., Stephan Bramow, Assunta Dal-Bianco, Claudia F. Lucchinetti, Helmut
536	Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, and Hans
537	Lassmann. "The Relation between Inflammation and Neurodegeneration in Multiple Sclerosis
538	Brains." Brain 132, no. 5 (May 2009): 1175–89. <u>https://doi.org/10.1093/brain/awp070</u> .
539	
540	[7] Brown, Robert A., Sridar Narayanan, and Douglas L. Arnold. "Imaging of Repeated Episodes
541	of Demyelination and Remyelination in Multiple Sclerosis." NeuroImage: Clinical 6 (2014): 20-
542	25. <u>https://doi.org/10.1016/j.nicl.2014.06.009</u> .
543	
544	[8] Wang, Chenyu Tim, Michael Barnett, and Yael Barnett. "Imaging the Multiple Sclerosis
545	Lesion: Insights into Pathogenesis, Progression and Repair." Current Opinion in Neurology 32,
546	no. 3 (June 2019): 338–45. <u>https://doi.org/10.1097/WCO.000000000000698</u> .
547	
548	[9] Thompson, Alan J, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee,
549	Giancarlo Comi, Jorge Correale, et al. "Diagnosis of Multiple Sclerosis: 2017 Revisions of the
550	McDonald Criteria." The Lancet Neurology 17, no. 2 (February 2018): 162–73.
551	https://doi.org/10.1016/S1474-4422(17)30470-2.

552

[10] Tabelow, Karsten, Evelyne Balteau, John Ashburner, Martina F. Callaghan, Bogdan
Draganski, Gunther Helms, Ferath Kherif, et al. "HMRI – A Toolbox for Quantitative MRI in
Neuroscience and Clinical Research." *NeuroImage* 194 (July 2019): 191–210.
<u>https://doi.org/10.1016/j.neuroimage.2019.01.029</u>.

558	[11] Schmierer, Klaus, Francesco Scaravilli, Daniel R. Altmann, Gareth J. Barker, and David H.
559	Miller. "Magnetization Transfer Ratio and Myelin in Postmortem Multiple Sclerosis Brain."
560	Annals of Neurology 56, no. 3 (September 2004): 407–15. <u>https://doi.org/10.1002/ana.20202</u> .
561	
562	[12] Callaghan, Martina F., Gunther Helms, Antoine Lutti, Siawoosh Mohammadi, and Nikolaus
563	Weiskopf. "A General Linear Relaxometry Model of R $_{1}$ Using Imaging Data: General Linear
564	Relaxometry Model of R1." Magnetic Resonance in Medicine 73, no. 3 (March 2015): 1309-
565	14. <u>https://doi.org/10.1002/mrm.25210</u> .
566	
567	[13] Van Waesberghe, J. H. T. M., W. Kamphorst, C. J. A. De Groot, M. A. A. Van Walderveen,
568	J. A. Castelijns, R. Ravid, G. J. Lycklama a Nijeholt, et al. "Axonal Loss in Multiple Sclerosis
569	Lesions: Magnetic Resonance Imaging Insights into Substrates of Disability." Annals of
570	<i>Neurology</i> 46, no. 5 (November 1999): 747–54. <u>https://doi.org/10.1002/1531-</u>
571	<u>8249(199911)46:5&lt;747::AID-ANA10&gt;3.0.CO;2-4</u> .
572	
573	[14] Mottershead, J. P., K. Schmierer, M. Clemence, J. S. Thornton, F. Scaravilli, G. J. Barker, P.
574	S. Tofts, et al. "High Field MRI Correlates of Myelin Content and Axonal Density in Multiple
575	Sclerosis." Journal of Neurology 250, no. 11 (November 1, 2003): 1293–1301.
576	<u>https://doi.org/10.1007/s00415-003-0192-3</u> .
577	
578	[15] Lema, Alfonso, Courtney Bishop, Omar Malik, Miriam Mattoscio, Rehiana Ali, Richard
579	Nicholas, Paolo A. Muraro, Paul M. Matthews, Adam D. Waldman, and Rexford D. Newbould.
580	"A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord

- 581 Microstructure in Multiple Sclerosis: MT of Brain and c-Spine in MS." *Journal of Neuroimaging*
- 582 27, no. 2 (March 2017): 221–26. <u>https://doi.org/10.1111/jon.12377</u>.
- 583
- 584 [16] Helms, Gunther, Henning Dathe, and Peter Dechent. "Modeling the Influence of TR and
- 585 Excitation Flip Angle on the Magnetization Transfer Ratio (MTR) in Human Brain Obtained
- 586 from 3D Spoiled Gradient Echo MRI." *Magnetic Resonance in Medicine* 64, no. 1 (July 2010):
- 587 177–85. <u>https://doi.org/10.1002/mrm.22379</u>.
- 588
- [17] Bagnato, Francesca, Simon Hametner, Emma Boyd, Verena Endmayr, Yaping Shi, Vasiliki
  Ikonomidou, Guanhua Chen, et al. "Untangling the R2\* Contrast in Multiple Sclerosis: A
  Combined MRI-Histology Study at 7.0 Tesla." Edited by Quan Jiang. *PLOS ONE* 13, no. 3 (March
- 592 21, 2018): e0193839. <u>https://doi.org/10.1371/journal.pone.0193839</u>.
- 593
- 594[18] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin595Haimburger, Christian Menard, et al. "The Influence of Brain Iron and Myelin on Magnetic596Susceptibility and Effective Transverse Relaxation A Biochemical and Histological Validation597Study."NeuroImage179(October2018):500Luc (10.1000)
- 598 <u>https://doi.org/10.1016/j.neuroimage.2018.06.007</u>.
- 599

[19] Stüber, Carsten, Markus Morawski, Andreas Schäfer, Christian Labadie, Miriam Wähnert,
Christoph Leuze, Markus Streicher, et al. "Myelin and Iron Concentration in the Human Brain:
A Quantitative Study of MRI Contrast." *NeuroImage* 93 (June 2014): 95–106.
<a href="https://doi.org/10.1016/j.neuroimage.2014.02.026">https://doi.org/10.1016/j.neuroimage.2014.02.026</a>.

605	[20] Stankiewicz, James M., Mohit Neema, et Antonia Ceccarelli. « Iron and Multiple
606	Sclerosis ». Neurobiology of Aging 35 (September 2014): S51-58.
607	https://doi.org/10.1016/j.neurobiolaging.2014.03.039.
608	
609	[21] Granziera, Cristina, Jens Wuerfel, Frederik Barkhof, Massimiliano Calabrese, Nicola De
610	Stefano, Christian Enzinger, Nikos Evangelou, et al. "Quantitative Magnetic Resonance
611	Imaging towards Clinical Application in Multiple Sclerosis." Brain 144, no. 5 (June 22, 2021):
612	1296–1311. <u>https://doi.org/10.1093/brain/awab029</u> .
613	
614	[22] Kolb, Hadar, Martina Absinta, Erin S. Beck, Seung-Kwon Ha, Yeajin Song, Gina Norato,

615 Irene Cortese, Pascal Sati, Govind Nair, and Daniel S. Reich. "7T MRI Differentiates 616 Remyelinated from Demyelinated Multiple Sclerosis Lesions." *Annals of Neurology* 90, no. 4

617 (October 2021): 612–26. <u>https://doi.org/10.1002/ana.26194</u>.

618

619 [23] Edwards, Luke J., Evgeniya Kirilina, Siawoosh Mohammadi, and Nikolaus Weiskopf.

620 "Microstructural Imaging of Human Neocortex in Vivo." *NeuroImage* 182 (November 2018):

621 184–206. <u>https://doi.org/10.1016/j.neuroimage.2018.02.055</u>.

622

[24] Lommers, Emilie, Jessica Simon, Gilles Reuter, Gaël Delrue, Dominique Dive, Christian
Degueldre, Evelyne Balteau, Christophe Phillips, and Pierre Maquet. "Multiparameter MRI
Quantification of Microstructural Tissue Alterations in Multiple Sclerosis." *NeuroImage: Clinical* 23 (2019): 101879. <u>https://doi.org/10.1016/j.nicl.2019.101879</u>.

[25] Lommers, Emilie, Camille Guillemin, Gilles Reuter, Eve Fouarge, Gaël Delrue, Fabienne 628 629 Collette, Christian Degueldre, Evelyne Balteau, Pierre Maquet, and Christophe Phillips. "VOXEL-630 BASED Quantitative MRI Reveals Spatial Patterns of Grey Matter Alteration in Multiple 631 Sclerosis." Human Brain Mapping (March 2021): 1003-12. 42, no. 4 632 https://doi.org/10.1002/hbm.25274.

633

[26] Andica, Christina, Akifumi Hagiwara, Koji Kamagata, Kazumasa Yokoyama, Keigo Shimoji,
Asami Saito, Yuki Takenaka, et al. "Gray Matter Alterations in Early and Late RelapsingRemitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance
Imaging." *Scientific Reports* 9, no. 1 (December 2019): 8147. <u>https://doi.org/10.1038/s41598-</u>

638 <u>019-44615-3</u>.

639

640 [27] Bonnier, Guillaume, Alexis Roche, David Romascano, Samanta Simioni, Djalel Meskaldji,

- 641 David Rotzinger, Ying-Chia Lin, et al. "Advanced MRI Unravels the Nature of Tissue Alterations
- in Early Multiple Sclerosis." Annals of Clinical and Translational Neurology 1, no. 6 (June 2014):
- 643 423–32. <u>https://doi.org/10.1002/acn3.68</u>.

644

[28] Engström, Maria, Jan B. M. Warntjes, Anders Tisell, Anne-Marie Landtblom, and Peter
Lundberg. "Multi-Parametric Representation of Voxel-Based Quantitative Magnetic
Resonance Imaging." Edited by Friedemann Paul. *PLoS ONE* 9, no. 11 (November 13, 2014):
e111688. <u>https://doi.org/10.1371/journal.pone.0111688</u>.

649

650 [29] Gracien, René-Maxime, Alina Jurcoane, Marlies Wagner, Sarah C. Reitz, Christoph Mayer,

651 Steffen Volz, Stephanie-Michelle Hof, et al. "Multimodal Quantitative MRI Assessment of

652	Cortical Damage in Relapsing-Remitting Multiple Sclerosis: Cortical Quantitative MRI in
653	RRMS." Journal of Magnetic Resonance Imaging 44, no. 6 (December 2016): 1600–1607.
654	https://doi.org/10.1002/jmri.25297.
655	
656	[30] Neema, Mohit, James Stankiewicz, Ashish Arora, Venkata S.R. Dandamudi, Courtney E.
657	Batt, Zachary D. Guss, Ali Al-Sabbagh, and Rohit Bakshi. "T1- and T2-Based MRI Measures of
658	Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis." Journal of
659	<i>Neuroimaging</i> 17 (April 2007): 16S-21S. <u>https://doi.org/10.1111/j.1552-6569.2007.00131.x</u> .
660	
661	[31] Reitz, Sarah C., Stephanie-Michelle Hof, Vinzenz Fleischer, Alla Brodski, Adriane Gröger,
662	René-Maxime Gracien, Amgad Droby, et al. "Multi-Parametric Quantitative MRI of Normal
663	Appearing White Matter in Multiple Sclerosis, and the Effect of Disease Activity on T2." Brain
664	Imaging and Behavior 11, no. 3 (June 2017): 744–53. <u>https://doi.org/10.1007/s11682-016-</u>
665	<u>9550-5</u> .
666	
667	[32] Stevenson, V.L, G.J.M Parker, G.J Barker, K Birnie, P.S Tofts, D.H Miller, and A.J Thompson.
668	"Variations in T1 and T2 Relaxation Times of Normal Appearing White Matter and Lesions in
669	Multiple Sclerosis." Journal of the Neurological Sciences 178, no. 2 (September 2000): 81–87.
670	https://doi.org/10.1016/S0022-510X(00)00339-7.
671	
672	[33] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Gregg Blevins, and Alan H. Wilman.
673	"Discriminative Analysis of Regional Evolution of Iron and Myelin/Calcium in Deep Gray Matter
674	of Multiple Sclerosis and Healthy Subjects: Analysis of Iron and Myelin in MS." Journal of

- 675 Magnetic Resonance Imaging 48, no. 3 (September 2018): 652–68.
  676 <u>https://doi.org/10.1002/jmri.26004</u>.
- 677
- 678 [34] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Peter Seres, Gregg Blevins, and Alan H.
- 679 Wilman. "Five Year Iron Changes in Relapsing-Remitting Multiple Sclerosis Deep Gray Matter
- 680 Compared to Healthy Controls." *Multiple Sclerosis and Related Disorders* 33 (August 2019):
- 681 107–15. <u>https://doi.org/10.1016/j.msard.2019.05.028</u>.
- 682
- [35] Khalil, M., C. Langkammer, A. Pichler, D. Pinter, T. Gattringer, G. Bachmaier, S. Ropele, S.
- Fuchs, C. Enzinger, and F. Fazekas. "Dynamics of Brain Iron Levels in Multiple Sclerosis: A
  Longitudinal 3T MRI Study." *Neurology* 84, no. 24 (June 16, 2015): 2396–2402.
  https://doi.org/10.1212/WNL.00000000001679.
- 687
- 688 [36] Gracien, René-Maxime, Sarah C. Reitz, Stephanie-Michelle Hof, Vinzenz Fleischer, Amgad
- 689 Droby, Mathias Wahl, Helmuth Steinmetz, Sergiu Groppa, Ralf Deichmann, and Johannes C.
- 690 Klein. "Longitudinal Quantitative MRI Assessment of Cortical Damage in Multiple Sclerosis: A
- 691 Pilot Study: Longitudinal Cortical QMRI in MS." Journal of Magnetic Resonance Imaging 46,
- 692 no. 5 (November 2017): 1485–90. <u>https://doi.org/10.1002/jmri.25685</u>.
- 693
- [37] Laule, Cornelia, I. M. Vavasour, K. P. Whittall, J. Oger, D. W. Paty, D. K. B. Li, A. L. MacKay,
  and D. L. Arnold. "Evolution of Focal and Diffuse magnetisation Transfer Abnormalities in
  Multiple Sclerosis." *Journal of Neurology* 250, no. 8 (August 2003): 924–31.
  https://doi.org/10.1007/s00415-003-1115-z.
- 698

[38] Hayton, T., J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter, D. J.

700 Tozer, D. H. Miller, and R. Kapoor. "Longitudinal Changes in Magnetisation Transfer Ratio in

- 701 Secondary Progressive Multiple Sclerosis: Data from a Randomised Placebo Controlled Trial of
- 702 Lamotrigine." Journal of Neurology 259, no. 3 (March 2012): 505–14.
- 703 <u>https://doi.org/10.1007/s00415-011-6212-9</u>.
- 704
- [39] Dousset, Vincent, Annick Gayou, Bruno Brochet, and Jean-Marie Caille. "Early Structural
   Changes in Acute MS Lesions Assessed by Serial Magnetization Transfer Studies." *Neurology*
- 707 51, no. 4 (October 1998): 1150–55. <u>https://doi.org/10.1212/WNL.51.4.1150</u>.
- 708
- [40] Levesque, Ives R., Paul S. Giacomini, Sridar Narayanan, Luciana T. Ribeiro, John G. Sled,
  Doug L. Arnold, and G. Bruce Pike. "Quantitative Magnetization Transfer and Myelin Water
  Imaging of the Evolution of Acute Multiple Sclerosis Lesions: Quantitative MT and T<sub>2</sub> in Acute
  MS Lesions." *Magnetic Resonance in Medicine* 63, no. 3 (March 2010): 633–40.
  https://doi.org/10.1002/mrm.22244.
- /15 <u>https://doi.org/10.1002/hhm.</u>
- 714

[41] Elskamp, Ij van den, DI Knol, H. Vrenken, G. Karas, A. Meijerman, M. Filippi, L. Kappos, et
al. "Lesional Magnetization Transfer Ratio: A Feasible Outcome for Remyelinating Treatment
Trials in Multiple Sclerosis." *Multiple Sclerosis Journal* 16, no. 6 (June 2010): 660–69.
<u>https://doi.org/10.1177/1352458510364630</u>.

719

[42] Filippi, Massimo, Maria A. Rocca, Gianvito Martino, Mark A. Horsfield, and Giancarlo
 Comi. "Magnetization Transfer Changes in the Normal Appering White Matter Precede the

- Appearance of Enhancing Lesions in Patients with Multiple Sclerosis." Annals of Neurology 43,
- 723 no. 6 (June 1998): 809–14. <u>https://doi.org/10.1002/ana.410430616</u>.
- 724
- 725 [43] Fazekas, F, S Ropele, C Enzinger, T Seifert, and S Strasser-Fuchs. "Quantitative 726 Magnetization Transfer Imaging of Pre-Lesional White-Matter Changes in Multiple Sclerosis." 727 Multiple Sclerosis Journal 6 (December 2002): 479-84. 8, no. 728 https://doi.org/10.1191/1352458502ms860oa.
- 729
- 730 [44] Draganski, B., J. Ashburner, C. Hutton, F. Kherif, R.S.J. Frackowiak, G. Helms, and N.
- 731 Weiskopf. "Regional Specificity of MRI Contrast Parameter Changes in Normal Ageing
- Revealed by Voxel-Based Quantification (VBQ)." *NeuroImage* 55, no. 4 (April 2011): 1423–34.
- 733 <u>https://doi.org/10.1016/j.neuroimage.2011.01.052</u>.
- 734
- 735 [45] Polman, Chris H., Stephen C. Reingold, Brenda Banwell, Michel Clanet, Jeffrey A. Cohen,
- 736 Massimo Filippi, Kazuo Fujihara, et al. "Diagnostic Criteria for Multiple Sclerosis: 2010
- Revisions to the McDonald Criteria." *Annals of Neurology* 69, no. 2 (February 2011): 292–302.
- 738 https://doi.org/10.1002/ana.22366.
- 739
- [46] Guillemin, C., E. Lommers, G. Delrue, E. Gester, P. Maquet, et F. Collette. « The Complex
  Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis ». *Psychologica Belgica* 62,
  nº 1 (March 2022): 108. <u>https://doi.org/10.5334/pb.1125</u>.
- 743
- 744

[47] Carey, Daniel, Francesco Caprini, Micah Allen, Antoine Lutti, Nikolaus Weiskopf, Geraint
Rees, Martina F. Callaghan, and Frederic Dick. "Quantitative MRI Provides Markers of Intra-,
Inter-Regional, and Age-Related Differences in Young Adult Cortical Microstructure." *NeuroImage* 182 (November 2018): 429–40.
<u>https://doi.org/10.1016/j.neuroimage.2017.11.066</u>.

750

751 [48] Reuter, Gilles, Emilie Lommers, Evelyne Balteau, Jessica Simon, Christophe Phillips, Felix 752 Scholtes, Didier Martin, Arnaud Lombard, and Pierre Maquet. "Multiparameter Quantitative 753 Histological MRI Values in High-Grade Gliomas: A Potential Biomarker of Tumor Progression." 754 Neuro-Oncology Practice (December 646-55. 7, 6 4, 2020): no. 755 https://doi.org/10.1093/nop/npaa047.

756

757 [49] Depierreux, Frédérique, Eric Parmentier, Laurane Mackels, Katherine Baquero, Christian

758 Degueldre, Evelyne Balteau, Eric Salmon, et al. "Parkinson's Disease Multimodal Imaging: F-

759 DOPA PET, Neuromelanin-Sensitive and Quantitative Iron-Sensitive MRI." Npj Parkinson's

760 *Disease* 7, no. 1 (December 2021): 57. <u>https://doi.org/10.1038/s41531-021-00199-2</u>.

761

[50] Nürnberger, Lucas, René-Maxime Gracien, Pavel Hok, Stephanie-Michelle Hof, Udo Rüb,
Helmuth Steinmetz, Rüdiger Hilker, Johannes C. Klein, Ralf Deichmann, and Simon Baudrexel.
"Longitudinal Changes of Cortical Microstructure in Parkinson's Disease Assessed with T1
Relaxometry." *NeuroImage: Clinical* 13 (2017): 405–14.
<u>https://doi.org/10.1016/j.nicl.2016.12.025</u>.

768 [51] Klein, J.C., M. Rolinski, L. Griffanti, K. Szewczyk-Krolikowski, F. Baig, C. Ruffmann, A.R.

769 Groves, R.A.L. Menke, M.T. Hu, and C. Mackay. "Cortical Structural Involvement and Cognitive

- 770 Dysfunction in Early Parkinson's Disease." *NMR in Biomedicine* 31, no. 4 (April 2018): e3900.
- 771 https://doi.org/10.1002/nbm.3900.
- 772

[52] Lutti, Antoine, Chloe Hutton, Jürgen Finsterbusch, Gunther Helms, and Nikolaus
Weiskopf. "Optimization and Validation of Methods for Mapping of the Radiofrequency
Transmit Field at 3T: Optimized RF Transmit Field Mapping at 3T." *Magnetic Resonance in Medicine* 64, no. 1 (July 2010): 229–38. https://doi.org/10.1002/mrm.22421.

777

[53] Lutti, Antoine, Joerg Stadler, Oliver Josephs, Christian Windischberger, Oliver Speck,
Johannes Bernarding, Chloe Hutton, and Nikolaus Weiskopf. "Robust and Fast Whole Brain
Mapping of the RF Transmit Field B1 at 7T." Edited by Wang Zhan. *PLoS ONE* 7, no. 3 (March

- 781 12, 2012): e32379. <u>https://doi.org/10.1371/journal.pone.0032379</u>.
- 782

783 [54] Filippi, M., Rocca, M. A., Horsfield, M. A., Hametner, S., Geurts, J. J., Comi, G., & Lassmann,

H. "Imaging cortical damage and dysfunction in multiple sclerosis." JAMA neurology, 70(5)

785 (May 2013): 556–564. https://doi.org/10.1001/jamaneurol.2013.1954

786

787 [55] Hulst, Hanneke E, and Jeroen JG Geurts. "Gray Matter Imaging in Multiple Sclerosis: What 788 Learned?" (December Have We ВМС Neurology 11, no. 1 2011): 153. 789 https://doi.org/10.1186/1471-2377-11-153.

- 790
- 791

792	[56] Schmidt, Paul, Christian Gaser, Milan Arsic, Dorothea Buck, Annette Förschler, Achim
793	Berthele, Muna Hoshi, et al. "An Automated Tool for Detection of FLAIR-Hyperintense White-
794	Matter Lesions in Multiple Sclerosis." NeuroImage 59, no. 4 (February 2012): 3774–83.
795	https://doi.org/10.1016/j.neuroimage.2011.11.032.
796	
797	[57] Weiskopf, Nikolaus, Martina F. Callaghan, Oliver Josephs, Antoine Lutti, and Siawoosh
798	Mohammadi. "Estimating the Apparent Transverse Relaxation Time (R2*) from Images with
799	Different Contrasts (ESTATICS) Reduces Motion Artifacts." Frontiers in Neuroscience 8
800	(September 10, 2014). <u>https://doi.org/10.3389/fnins.2014.00278</u> .
801	
802	[58] Preibisch, C., and R. Deichmann. "Influence of RF Spoiling on the Stability and Accuracy of
803	$T_1$ Mapping Based on Spoiled FLASH with Varying Flip Angles: Influence of RF Spoiling on $T_1$
804	Mapping." Magnetic Resonance in Medicine 61, no. 1 (January 2009): 125–35.
805	https://doi.org/10.1002/mrm.21776.
806	
807	[59] Ashburner, John. "Symmetric Diffeomorphic Modeling of Longitudinal Structural MRI."
808	Frontiers in Neuroscience 6 (2013). https://doi.org/10.3389/fnins.2012.00197.
809	
810	[60] Ashburner, John, and Karl J. Friston. "Unified Segmentation." NeuroImage 26, no. 3 (July
811	2005): 839–51. <u>https://doi.org/10.1016/j.neuroimage.2005.02.018</u> .
812	
813	[61] Lorio, S., S. Fresard, S. Adaszewski, F. Kherif, R. Chowdhury, R.S. Frackowiak, J. Ashburner,
814	et al. "New Tissue Priors for Improved Automated Classification of Subcortical Brain Structures

- 815 on MRI." NeuroImage 130 (April 2016): 157–66. 816 https://doi.org/10.1016/j.neuroimage.2016.01.062. 817 [62] Andersen, Sarah M., Steven Z. Rapcsak, and Pélagie M. Beeson. "Cost Function Masking 818 819 during Normalization of Brains with Focal Lesions: Still a Necessity?" NeuroImage 53, no. 1 820 (October 2010): 78-84. https://doi.org/10.1016/j.neuroimage.2010.06.003. 821 822 [63] Moon, Nathan, Elizabeth Bullitt, Koen van Leemput, and Guido Gerig. "Automatic Brain 823 and Tumor Segmentation." In Medical Image Computing and Computer-Assisted Intervention 824 - MICCAI 2002, edited by Takeyoshi Dohi and Ron Kikinis, 2488:372–79. Lecture Notes in 825 Computer Science. Berlin, Heidelberg: Berlin Heidelberg, 2002. Springer
- 826 <u>https://doi.org/10.1007/3-540-45786-0\_46</u>.
- 827
- 828 [64] Pandit, Lekha. "No Evidence of Disease Activity (NEDA) in Multiple Sclerosis Shifting the
- 829 Goal Posts." Annals of Indian Academy of Neurology 22, no. 3 (2019): 261.
- 830 https://doi.org/10.4103/aian.AIAN 159 19.
- 831
- 832 [65] Anderson, Marti J. "Permutation Tests for Univariate or Multivariate Analysis of Variance
- and Regression." Canadian Journal of Fisheries and Aquatic Sciences 58, no. 3 (March 1, 2001):
- 834 626–39. <u>https://doi.org/10.1139/f01-004</u>.
- 835
- 836 [66] Yoav Benjamini and Yosef Hochberg. "Controlling the False Discovery Rate: a Practical and
- 837 Powerful Approach to Multiple Testing" Journal of the Royal Statistical Society. Series B
- 838 (*Methodological*), Vol. 57, No.1 (1995), 289-300.

```
839
```

[67] Leutritz, Tobias, Maryam Seif, Gunther Helms, Rebecca S Samson, Armin Curt, Patrick
Freund, and Nikolaus Weiskopf. "Multiparameter Mapping of Relaxation (R1, R2 \*), Proton
Density and Magnetization Transfer Saturation at 3 T: A Multicenter Dual-vendor
Reproducibility and Repeatability Study." *Human Brain Mapping* 41, no. 15 (October 15,
2020): 4232–47. https://doi.org/10.1002/hbm.25122.

845

846 [68] Bonnier, Guillaume, Benedicte Maréchal, Mário João Fartaria, Pavel Falkowskiy, José P. 847 Marques, Samanta Simioni, Myriam Schluep, et al. "The Combined Quantification and 848 Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens 849 Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis 850 Patients." Frontiers in Neurology 8 (September 27, 2017): 506. 851 https://doi.org/10.3389/fneur.2017.00506.

852

[69] Rocca, Maria A, Giovanna Mastronardo, Mariemma Rodegher, Giancarlo Comi, and
Massimo Filippi. "Long-Term Changes of Magnetization Transfer-Derived Measures from
Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis," *AJNR Am J Neuroradiol* 20 (1999):821–827

857

858 [70] Callaghan, Martina F., Patrick Freund, Bogdan Draganski, Elaine Anderson, Marinella 859 Cappelletti, Rumana Chowdhury, Joern Diedrichsen, et al. "Widespread Age-Related 860 Differences in the Human Brain Microstructure Revealed by Quantitative Magnetic Resonance 861 Imaging." Neurobiology of Aging 35, no. 8 (August 2014): 1862-72. https://doi.org/10.1016/j.neurobiolaging.2014.02.008. 862

## 863

[71] Weiskopf, Nikolaus, Siawoosh Mohammadi, Antoine Lutti, and Martina F. Callaghan.
"Advances in MRI-Based Computational Neuroanatomy: From Morphometry to in-Vivo
Histology." *Current Opinion in Neurology* 28, no. 4 (August 2015): 313–22.
https://doi.org/10.1097/WCO.0000000000222.

868

869 [72] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin

870 Haimburger, Christian Menard, et al. "The Influence of Brain Iron and Myelin on Magnetic

871 Susceptibility and Effective Transverse Relaxation - A Biochemical and Histological Validation

- 872 Study." NeuroImage 179 (October 2018): 117–33.
- 873 <u>https://doi.org/10.1016/j.neuroimage.2018.06.007</u>.
- 874

[73] Mangeat, G., S.T. Govindarajan, C. Mainero, and J. Cohen-Adad. "Multivariate
Combination of Magnetization Transfer, T 2 \* and B0 Orientation to Study the MyeloArchitecture of the in Vivo Human Cortex." *NeuroImage* 119 (October 2015): 89–102.
https://doi.org/10.1016/j.neuroimage.2015.06.033.

879

[74] Dutta, R., and B. D. Trapp. "Pathogenesis of Axonal and Neuronal Damage in Multiple
Sclerosis." *Neurology* 68, no. Issue 22, Supplement 3 (May 29, 2007): S22–31.
<u>https://doi.org/10.1212/01.wnl.0000275229.13012.32</u>.

883

[75] Frischer, Josa M., Stephen D. Weigand, Yong Guo, Nilufer Kale, Joseph E. Parisi, Istvan
Pirko, Jay Mandrekar, et al. "Clinical and Pathological Insights into the Dynamic Nature of the

- 886 White Matter Multiple Sclerosis Plaque: Dynamic Nature of MS Plaque." Annals of Neurology
- 887 78, no. 5 (November 2015): 710–21. https://doi.org/10.1002/ana.24497.

- 889 [76] Lassmann, Hans, Wolfgang Brück, and Claudia Lucchinetti. "Heterogeneity of Multiple
- 890 Sclerosis Pathogenesis: Implications for Diagnosis and Therapy." Trends in Molecular Medicine
- 891 7, no. 3 (March 2001): 115–21. https://doi.org/10.1016/S1471-4914(00)01909-2.
- 892
- 893 [77] Lucchinetti, Claudia, Wolfgang Brück, Joseph Parisi, Bernd Scheithauer, Moses Rodriguez,
- 894 and Hans Lassmann. "Heterogeneity of Multiple Sclerosis Lesions: Implications for the
- 895 Pathogenesis of Demyelination." Annals of Neurology 47, no. 6 (June 2000): 707-17.
- 896 https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q.
- 897
- 898 [78] Zheng, Yufan, Jar-Chi Lee, Richard Rudick, and Elizabeth Fisher. "Long-Term 899 Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions: Long-Term 900 MTR Evolution in MS WM Lesions." Journal of Neuroimaging 28, no. 2 (March 2018): 191–98.
- 901 https://doi.org/10.1111/jon.12480.
- 902
- 903 [79] Chawla, Sanjeev, Ilya Kister, Tim Sinnecker, Jens Wuerfel, Jean-Christophe Brisset, 904 Friedemann Paul, and Yulin Ge. "Longitudinal Study of Multiple Sclerosis Lesions Using Ultra-905 High Field (7T) Multiparametric MR Imaging." Edited by Quan Jiang. PLOS ONE 13, no. 9 (September 13, 2018): e0202918. <u>https://doi.org/10.1371/journal.pone.0202918</u>. 906 907
- 908 [80] Lieury, Alice, Marie Chanal, Géraldine Androdias, Richard Reynolds, Sylvie Cavagna, Pascale Giraudon, Christian Confavreux, and Serge Nataf. "Tissue Remodeling in Periplaque 909

- 910 Regions of Multiple Sclerosis Spinal Cord Lesions: Glia Remodeling in MS Spinal Cord." *Glia* 62,
- 911 no. 10 (October 2014): 1645–58. <u>https://doi.org/10.1002/glia.22705</u>.
- 912
- 913 [81] Kuhlmann, Tanja, Samuel Ludwin, Alexandre Prat, Jack Antel, Wolfgang Brück, and Hans
- 914 Lassmann. "An Updated Histological Classification System for Multiple Sclerosis Lesions." Acta
- 915 Neuropathologica 133, no. 1 (January 2017): 13–24. https://doi.org/10.1007/s00401-016-
- 916 <u>1653-y</u>.
- 917
- 918 [82] Lassmann, Hans, Wolfgang Brück, and Claudia F. Lucchinetti. "The Immunopathology of
- 919 Multiple Sclerosis: An Overview." Brain Pathology 17, no. 2 (April 2007): 210–18.
- 920 <u>https://doi.org/10.1111/j.1750-3639.2007.00064.x</u>.
- 921
- 922 [83] Hametner, Simon, Isabella Wimmer, Lukas Haider, Sabine Pfeifenbring, Wolfgang Brück,
- 923 and Hans Lassmann. "Iron and Neurodegeneration in the Multiple Sclerosis Brain." Annals of
- 924 *Neurology* 74, no. 6 (December 2013): 848–61. <u>https://doi.org/10.1002/ana.23974</u>.
- 925
- 926 [84] Popescu, Bogdan F., Josa M. Frischer, Samuel M. Webb, Mylyne Tham, Reginald C. Adiele,
- 927 Christopher A. Robinson, Patrick D. Fitz-Gibbon, et al. "Pathogenic Implications of Distinct
- 928 Patterns of Iron and Zinc in Chronic MS Lesions." Acta Neuropathologica 134, no. 1 (July 2017):
- 929 45–64. <u>https://doi.org/10.1007/s00401-017-1696-8</u>.
- 930
- [85] De Stefano, N., A. Giorgio, M. Battaglini, M. Rovaris, M. P. Sormani, F. Barkhof, T.
  Sorteweg, et al. "Assessing Brain Atrophy Rates in a Large Population of Untreated Multiple

- 933 Sclerosis Subtypes." Neurology 74, no. 23 (June 8, 2010): 1868–76.
  934 <u>https://doi.org/10.1212/WNL.0b013e3181e24136</u>.
- 935
- 936 [86] Eshaghi, Arman, Ferran Prados, Wallace J. Brownlee, Daniel R. Altmann, Carmen Tur, M.
- 937 Jorge Cardoso, Floriana De Angelis, et al. "Deep Gray Matter Volume Loss Drives Disability
- 938 Worsening in Multiple Sclerosis: Deep Gray Matter Volume Loss." Annals of Neurology 83, no.
- 939 2 (February 2018): 210–22. <u>https://doi.org/10.1002/ana.25145</u>.
- 940
- 941 [87] Bermel, Robert A, and Rohit Bakshi. "The Measurement and Clinical Relevance of Brain
- 942 Atrophy in Multiple Sclerosis." The Lancet Neurology 5, no. 2 (February 2006): 158–70.
- 943 <u>https://doi.org/10.1016/S1474-4422(06)70349-0</u>.
- 944
- 945 [88] Zivadinov, R., A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M.
- 946 G. Dwyer, E. M. Frohman, and O. Khan. "Mechanisms of Action of Disease-Modifying Agents
- 947 and Brain Volume Changes in Multiple Sclerosis." *Neurology* 71, no. 2 (July 8, 2008): 136–44.
- 948 https://doi.org/10.1212/01.wnl.0000316810.01120.05.
- 949
- 950 [89] De Stefano, Nicola, Maria Laura Stromillo, Antonio Giorgio, Maria Letizia Bartolozzi, 951 Marco Battaglini, Mariella Baldini, Emilio Portaccio, Maria Pia Amato, and Maria Pia Sormani. 952 "Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple Sclerosis." Journal of 953 Neurology, Neurosurgery & Psychiatry, April 22, 2015, jnnp-2014-309903. 954 https://doi.org/10.1136/jnnp-2014-309903.
- 955

- [90] Christian Enzinger, Frederik Barkhof, Olga Ciccarelli, Massimo Filippi, Ludwig Kappos,
  Maria A. Rocca, et al. "Nonconventional MRI and Microstructural Cerebral Changes in Multiple
  Sclerosis." *Nature Reviews Neurology* 11, no. 12 (December 2015): 676–86.
- 959 <u>https://doi.org/10.1038/nrneurol.2015.194</u>.
- 960

[91] Bodini, Benedetta, Mattia Veronese, Daniel García-Lorenzo, Marco Battaglini, Emilie
Poirion, Audrey Chardain, Léorah Freeman, et al. "Dynamic Imaging of Individual
Remyelination Profiles in Multiple Sclerosis." *Annals of Neurology* 79, no. 5 (May 2016): 726–

- 964 38. <u>https://doi.org/10.1002/ana.24620</u>.
- 965

966 [92] Patrikios, P., C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H. Laursen, P.

967 S. Sorensen, W. Bruck, C. Lucchinetti, and H. Lassmann. "Remyelination Is Extensive in a Subset 968 of Multiple Sclerosis Patients." *Brain* 129, no. 12 (June 9, 2006): 3165–72.

- 969 <u>https://doi.org/10.1093/brain/awl217</u>.
- 970
- [93] Gracien, RM., Nürnberger, L., Hok, P. *et al.* Evaluation of brain ageing: a quantitative
  longitudinal MRI study over 7 years. *Eur Radiol* 27, 1568–1576 (2017).
  https://doi.org/10.1007/s00330-016-4485-1
- 974

#### Tables 975

	All Patients (n = 17)		
Age, y, median (range)	36 (25-65)		
Sex, F/M	7/10		
MS phenotype (RRMS/MS)	11/6		
Baseline disease duration, y, median (range)	3.4 (0.3-28)		
Baseline EDSS, median (range)	2.5 (1-6.5)		
Baseline number of relapses, median (range)	<b>RRMS</b> : 2 (1-5)	<b>PMS</b> : N/A	
	RRMS:	PMS:	
Disease-modifying treatment	First line, n: 5	Ocrelizumab, n: 2	
	Second line, n: 6	None, n: 4	

976

977

Table 1: Demographic data of the study sample

979

	EDSS T0	EDSS T1/2	New lesion T1/2	Relapse T1/2	NEDA T1/2	EDSS T1	New lesion T1	Relapse T1	NEDA T1	Time period T0-T1	Score
sub-001	2	2	None	None	YES	2	None	None	YES	30	1
sub-002	1.5	1.5	None	None	YES	1.5	None	None	YES	27	1
sub-003	2	2	None	None	YES	2	None	None	YES	27	1
sub-004	3	3	None	None	YES	3.5	None	None	YES	25	1
sub-005	1	1	None	None	YES	1	None	None	YES	24	1
sub-006	1.5	1.5	None	None	YES	1.5	None	None	YES	24	1
sub-007	2	2	None	None	YES	2	None	None	YES	22	1
sub-008	3.5	4.5	None	N/A	NO	5	None	N/A	NO	51	0
sub-009	2	2.5	None	None	YES	2.5	None	None	YES	57	1
sub-010	6	6	Yes	N/A	NO	6.5	None	None	NO	14	0
sub-011	6	6	None	N/A	YES	6.5	None	N/A	NO	14	1
sub-012	1	1.5	None	None	YES	1.5	None	None	YES	55	1
sub-013	5.5	6	None	N/A	NO	6.5	None	N/A	NO	60	0
sub-014	2.5	3.5	Yes	Yes	NO	3	None	None	YES	57	1
sub-015	4	4.5	None	N/A	NO	5	None	N/A	NO	51	0
sub-016	5	4.5	Yes	N/A	NO	4.5	None	N/A	YES	61	1
_sub-017	2	3	Yes	Yes	NO	3	Yes	Yes	NO	56	0

980

981 Table 2: Longitudinal clinical information and derived disease status score. The time period 982 between T0 and T1 is expressed in months.

983

	NAWM	NACGM	NADGM	
MTsat	0.039 (.011)*	0.039 (.011)* 0.017 (.007)*		
PD	-0.018 (.670)	0.405 (.225)	0.250 (.552)	
R1	0.009 (.139)	0.004 (.471)	0.010 (.111)	
R2*	<b>0.295 (.002)*</b> 0.121 (.092)		0.066 (.770)	
BPF	-0.884 (.1562)			
LF	21.23 (.1082)			

984

988

985 Table 3: Regression coefficients and their associated p-values (in parentheses) for the effects of  $X_{status}$  on the individual ARoC for each qMRI parameter (MTsat, PD, R1 and 986

987 R2\*) and for volumetric measurements (BPF and LF).

\* Results significant at p < .05, FDR corrected.

It is made available	under a CC-BY	4.0 International	icense

#### Legends of figures 990

992	Figure 1: Chartflow of data creation and processing (see text). MPM maps were created with
993	the hMRI-toolbox, FLAIR images were directly acquired for both sessions (T0 and T1). A
994	preliminary mask was constructed based on TO FLAIR. All images (MPM and FLAIR, TO and
995	T1) were co-registered to the MPM T0 space. Segmentation using USwL allowed to isolate
996	the different tissue classes.
997	
998	Figure 2: Schematic illustration of the NAWM and 3 lesions-related areas: focal FLAIR lesion
999	(dark gray area), initial peripheral lesion detected at TO (medium gray area), later peripheral
1000	lesion detected at T1 (dashed, left, and light gray, right, area).
1001	
1002	Figure 3: Line plots illustrating individual ARoC's for MTsat (left) and R2* (right) in NAWM.
1003	Each line corresponds to one subject. Dotted lines represent increasing rates.
1004	
1005	<b>Figure 4:</b> Violin plots of significant change rates in microstructure with respect to $X_{status}$ .
1006	From left to right: MTsat in NAWM, MTsat in NACGM, R2* in NAWM. * $P < .05$ .
1007	
1008	Figure 5: Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time
1009	T0 and T1. P-values were obtained with <i>post-hoc</i> tests on the tissue area effect. * $P < .05$ .
1010	
1011	

perpetany.
It is made available under a CC-BY 4.0 International license.

Appendix A: Supplementary data legends
Supplementary data 1: Multi-echo 3D FLASH acquisition parameters for Siemens Magnetom PRISMA MRI
<b>Supplementary data 2:</b> Extended demographic data. Age, disease duration, EDSS and relapses values were taken at baseline.
Supplementary data 3: Additional follow-up clinical data for each subject.
Supplementary data 4: Line plots illustrating individual ARoC's for PD (left) and R1 (right) in NAWM. Each line corresponds to one subject. Dotted lines represent increasing rates.
<b>Supplementary data 5:</b> Differences of lesion class Least Squares Means. First two columns correspond to tissue class labels (0 = NAWM, 1 = Later peripheral lesion, 2 = Initial peripheral lesion, 3 = FLAIR lesion).



**Figure 1:** Chartflow of data creation and processing (see text). MPM maps were created with the hMRI-toolbox, FLAIR images were directly acquired for both sessions (T0 and T1). A preliminary mask was constructed based on T0 FLAIR. All images (MPM and FLAIR, T0 and T1) were co-registered to the MPM T0 space. Segmentation using USwL allowed to isolate the different tissue classes.



Figure 2: Schematic illustration of the NAWM and 3 lesions-related areas: focal FLAIR lesion (dark gray area), initial peripheral lesion detected at TO (medium gray area), later peripheral lesion detected at T1 (dashed, left, and light gray,

right, area)





Each line corresponds to one subject. Dotted lines represent increasing rates.



**Figure 4:** Violin plots of significant change rates in microstructure with respect to  $X_{status}$ .

From left to right: MTsat in NAWM, MTsat in NACGM, R2\* in NAWM. \* P < .05.



Figure 5: Microstructural parameters in NAWM and the 3 lesion-related areas,

for each scanning time T0 and T1. P-values were obtained with *post-hoc* tests on

the tissue area effect. \* P < .05.